Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;51(5):597-599.
doi: 10.1016/j.ajic.2022.09.021. Epub 2022 Sep 20.

Standing-up COVID-19 monoclonal antibody infusion centers: Infection prevention and control

Brooke Brewer  1 , Pamela Del Monte  2 , Pamela Blair Miller  2 , Lisa Teal  2 , Emily E Sickbert-Bennett  3 , Lauren M DiBiase  3 , David J Weber  3 , Deanna Harris  2 , David Wohl  3
Affiliations

Standing-up COVID-19 monoclonal antibody infusion centers: Infection prevention and control

Brooke Brewer et al. Am J Infect Control. 2023 May.

Abstract

This paper describes the creation of outpatient monoclonal antibody (mAb) infusion centers for COVID-19 patients in a large academic medical center. It shows how the early and consistent partnership between infection prevention and the clinical and operational teams to establish and implement policies and procedures led to efficient and safe workflows.

Keywords: Emergency use authorization; Prophylaxis.

PubMed Disclaimer

Figures

Figure 1:
Figure 1
Clinic infusion area diagram.
See this image and copyright information in PMC

References

    1. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2020;384:229–237. - PMC - PubMed
    1. FDA Authorizes REGEN-COV Monoclonal Antibody Therapy for Post-exposure Prophylaxis (prevention) for COVID-19. FDA. [online] (2021). Accessed July 13, 2021.https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-re...
    1. FDA Authorizes Bamlanivimab and Etesevimab Monoclonal Antibody Therapy for Post-exposure Prophylaxis (prevention) for COVID-19. FDA. [online] (2021). Accessed July 13, 2021.https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-ba...

Substances